Comparing multiple myeloma treatment with and without dexamethasone
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests whether adding dexamethasone to an antibody-based combination therapy works better for multiple myeloma that has come back after previous treatments. If you have had 1 to 3 prior therapies and are eligible for one of two standard drug regimens, this study may help find the best approach for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your multiple myeloma has come back after 1 to 3 prior treatments.
- You have had a good partial response or better to your last therapy.
- You are eligible for either isatuximab plus pomalidomide or isatuximab plus carfilzomib.
- You are not refractory or intolerant to anti-CD38 antibody drugs.
- You have not had an allogeneic stem cell transplant and are not planning a stem cell transplant before the disease gets worse.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug for people with multiple myeloma, a type of blood cancer. It's for those who are newly diagnosed or whose cancer has come back or stopped responding to treatment. The goal is to see if the drug can control the disease.
This clinical trial tests a new combination of two medicines (cemsidomide and dexamethasone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new drug can help control the cancer when other options have stopped working.
This trial tests different dosing schedules of three drugs (belantamab mafodotin, bortezomib, and dexamethasone) together to treat multiple myeloma that has come back or stopped responding to previous treatments. The goal is to find a dosing plan that works well and is tolerable for patients.
This trial tests a new combination of two drugs (etentamig and daratumumab) against the current standard of daratumumab plus lenalidomide and dexamethasone in people recently diagnosed with multiple myeloma who cannot have a stem cell transplant. The goal is to see which combination better controls the disease while keeping side effects manageable.
This study tests a combination of three cancer drugs (belantamab mafodotin, bortezomib, and dexamethasone) in people with multiple myeloma who have had prior treatment and moderate liver function problems. The goal is to see if this combination works safely in patients whose cancer has come back or worsened.
This trial tests a combination of three drugs (elranatamab, lenalidomide, and dexamethasone) for people newly diagnosed with multiple myeloma. The goal is to see if this treatment can lead to a very deep response (no detectable cancer cells) in the bone marrow.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.